SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as investors digest a major revenue beat alongside the announcement of massive long-term hyperscaler contracts, fueling intense debate between bulls who see a scaling cash-flow machine and bears concerned about capital expenditure and dilution. The community is focused on the company's aggressive infrastructure buildout timeline and the potential for these contracted revenue milestones to drive long-term value despite broader market volatility.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is facing intense scrutiny as FDA briefing documents ahead of the advisory committee meeting highlight concerns regarding statistical analysis plan modifications, leading to a significant market sell-off. Community members are actively debating whether these discrepancies represent data manipulation, as the FDA suggests, or a breakdown in regulatory communication and administrative incompetence regarding the validity of the final trial plan.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is currently trading in a tight range as the community intensely debates the potential passage of the Clarity Act and its impact on institutional adoption. Investors remain polarized, with many aggressively accumulating on dips in anticipation of regulatory breakthroughs while others express frustration over stagnant price action and the influence of broader political uncertainty.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is facing intense downward pressure driven by concerns over circular financing structures related to massive AI infrastructure commitments and potential credit risks. Investors are actively debating whether these financing models are a sign of long-term AI demand or a signal that the AI buildout is approaching an unsustainable peak.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing high volatility driven by conflicting signals regarding semiconductor demand and broader market geopolitical risks. Community sentiment is deeply divided, with many traders debating whether the stock is trapped in a bearish cycle or poised for a rapid recovery following earnings-related momentum.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing heightened volatility as investors grapple with a combination of intensifying geopolitical tensions in the Middle East and concerns over the sustainability of AI-driven capital expenditures. Market participants are actively debating the timing of potential Federal Reserve rate adjustments and monitoring the impact of a sharp downturn in the South Korean KOSPI index on broader technology valuations.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending amid significant market volatility as investors debate the sustainability of AI infrastructure spending and its impact on semiconductor valuations. The community remains deeply divided between those betting on long-term growth driven by new AI hardware partnerships and those anticipating a sharp correction due to concerns over bloated PE ratios and macroeconomic headwinds.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

MapLight Therapeutics Inc.

MapLight Therapeutics is seeing intense volatility after its Phase 2 schizophrenia trial yielded mixed results, with investors sharply divided on whether the significant sell-off is an overreaction to the missed endpoint or a justified response to the trial data. Community members are actively debating the company's valuation, cash position, and institutional ownership while weighing the prospects of a potential recovery against the inherent risks of biotech value traps.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as the market digests its recent quarterly earnings, where it delivered strong results and positive guidance that underscored the critical role of its advanced packaging services in the AI semiconductor supply chain. Investors and community members are actively debating the stock's valuation and volatility, with many highlighting its strategic partnership for U.S.-based chip packaging as a key long-term catalyst amidst a broader, multi-year semiconductor growth cycle.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin shareholders are focused on upcoming Supreme Court litigation and first-quarter financial results, as the community debates the company's valuation and the potential for a strategic buyout. While some investors remain optimistic about the long-term impact of new formulation developments, others are expressing frustration over stagnant price action and management's transparency.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?

Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else New Treatment Modalities Are Reaching Cancers That Resisted Everything Else PR Newswire VANCOUVER, BC, Feb. 17, 2026 Issued...

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...

Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates

Stevanato (STVN) delivered earnings and revenue surprises of +14.29% and +5.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of +56.99% and +12.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +46.96% and +21.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of +46.15% and +39.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates

electroCore (ECOR) delivered earnings and revenue surprises of -9.38% and +0.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates

Amneal (AMRX) delivered earnings and revenue surprises of +38.89% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

The Fed's July 28-29 meeting has markets debating a hold versus a hike, not a cut, with CME FedWatch pricing roughly a 65% chance of no change and rising odds of a September rate increase amid inflation running well above the 2% target. What do you expect the Fed to decide? Drop a comment with when you expect the first cut/hike to be.

What do you expect the Fed to decide at its FOMC meeting?  
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CATXPerspective Therapeutics Inc

Fundamentals

Latest CATX News